Search clinical trials for: MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days

Total 243 results

Merck Sharp & Dohme LLC

Completed

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Renal Insufficiency | Hemodialysis
Merck Sharp & Dohme LLC

Completed

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Type 2 Diabetes Mellitus
Organon and Co

Completed

Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)

Migraine
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Completed

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Diabetes Mellitus, Type 2
Organon and Co

Completed

Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)

Migraine
Organon and Co

Completed

Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)

Migraine
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Liver Insufficiency
Organon and Co

Completed

Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)

Migraine
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)

Diabetes Mellitus Non-insulin-dependent
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
Ipsen

Completed

Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children

Diarrhoea

Malaysia
Ipsen

Completed

Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children

Diarrhoea

Peru
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Diabetes Mellitus Non-insulin-dependent
Merck Sharp & Dohme LLC

Completed

Sitagliptin Added-on to Insulin Study (0431-051)

Type 2 Diabetes Mellitus
Enanta Pharmaceuticals, Inc

Unknown

Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia

Community Acquired Pneumonia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)

Diabetes Mellitus, Type 2 | Chronic Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

Type 2 Diabetes Mellitus
Ipsen

Terminated

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Thyroid-Associated Ophthalmopathy

Spain
Merck Sharp & Dohme LLC

Completed

Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)

Urinary Tract Infections | Soft Tissue Infections | Bacterial Pneumonia
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Pneumonia | Infection
Sunnybrook Health Sciences Centre
Queen's University

Completed

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT (BALANCE)

Bacteremia

Canada
Merck Sharp & Dohme LLC

Completed

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)

Pain, Postoperative Arthroscopy
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
Merck Sharp & Dohme LLC

Completed

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Diabetes Mellitus, Non-Insulin-Dependent
H. Lundbeck A/S

Terminated

Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

Type 2 Diabetes
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sitagliptin for Reducing Inflammation and Immune Activation

HIV-1 Infection

United States
Organon and Co

Completed

A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)

Coronary Disease
Merck Sharp & Dohme LLC

Completed

Upper GI Handling of Branded vs. Generic Alendronate

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Type 2 Diabetes Mellitus
Takeda

Completed

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC
Duke Clinical Research Institute, Oxford Diabetes Trials Unit

Completed

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (TECOS)

Type 2 Diabetes Mellitus
GlaxoSmithKline

Completed

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

Diabetes Mellitus, Type 2

United States, Germany, Peru, Israel, Taiwan, Australia, Russian Federation, United Kingdom, Korea, Republic of, Spain, Brazil, Colombia, India, Philippines, South Africa

3

Subscribe